Ligand-Based Virtual Screening as a Path to New Chemotypes for Candidate PET Radioligands for Imaging Tauopathies.
Bryan T HurtleSusovan JanaLisheng CaiVictor W PikePublished in: Journal of medicinal chemistry (2024)
Ligand-based virtual screening (LBVS) has rarely been tested as a method for discovering new structural scaffolds for PET radioligand development. This study used LBVS to discover potential chemotype leads for developing radioligands for PET imaging of tauopathies. ZINC12, a free database of over 12 million commercially available compounds, was searched to discover novel scaffolds based on similarities to four query compounds. Thirteen high-ranking hits were purchased and assayed for their ability to compete against three tritiated radioligands at their distinct binding sites in Alzheimer's disease brain tissue. Three hits were 2-substituted 6-methoxy naphthalenes. Synthetic elaboration of this new chemotype yielded three new ligands ( 25 , 26 , and 28 ) with high affinity for the [ 3 H] 6 (flortaucipur) neurofibrillary tangle binding site. Compound 28 showed remarkably high affinity ( K i , 7 nM) and other desirable properties for a candidate PET radioligand, including low topological polar surface area, moderate computed log D , and amenability for labeling with carbon-11. LBVS appears to be uniquely valuable for discovering new chemotypes for candidate PET radioligands.
Keyphrases
- pet imaging
- positron emission tomography
- pet ct
- computed tomography
- magnetic resonance imaging
- high resolution
- emergency department
- tissue engineering
- multiple sclerosis
- photodynamic therapy
- white matter
- molecular docking
- mass spectrometry
- molecular dynamics simulations
- contrast enhanced
- human health
- risk assessment
- subarachnoid hemorrhage
- cerebral ischemia
- oxide nanoparticles
- adverse drug